COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Just a week after the FDA updated its stance on new COVID-19 | The CDC's recommended immunization schedule no longer includes ...

AbbVie’s Allergan aesthetics unit is tightening up its workforce with 202 layoffs. | The layoffs at Allergan's Irvine, ...

Following a string of vaccine expansion projects last year, Sanofi is eyeing a new path to potentially grow the reach of its ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...